HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

US FDA Food Safety Chief Looks Back On Full Plate Of Challenges, Funding Basket In Need Of More

Executive Summary

“We don't have to look much further than our consumer complaint and adverse event systems to see that these upgrades are needed. Each year we receive nearly 10,000 consumer complaints and adverse event reports regarding FDA regulated foods and dietary supplements,” says Susan Mayne.

You may also be interested in...



OTC Drugs, Dietary Supplements Merit Scant Mention In $7.2Bn FDA FY2024 Budget Request

Supplements and OTC drug categories each mentioned once in FY2024 budget request for agency published by HHS. Broader document provided by White House OMB makes no mention of either category while emphasizing proposed increase for FDA’s food programs.

Absent Mandatory Listing, US FDA Acknowledges Its Supplement Directory Isn’t Comprehensive

Two weeks after Commissioner Califf notes he supports mandatory listing of supplements and two months after previous session of Congress ended without imposing requirement, agency is doing what it can to publish information about ingredients in supplements sold in the country.

USDA Examines Potential Production Regulation Changes To Prevent Powder Formula Contamination

USDA Food Safety and Inspection Service’s National Advisory Committee on Microbiological Criteria for Foods schedules hearing for 15 November to consider a report from FDA on presence of Cronobacter species bacteria in powder formula products.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS153676

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel